The UK board of Oncimmune is:
|Meinhard Schmidt||- Non Executive Chairman|
|Geoffrey Hamilton-Fairley||- Chief Executive Officer|
|Andrew Millet||- Chief Financial Officer|
|Tim Bunting||- Non-Executive Director (Deputy Chairman)|
|Julian Hirst||- Non-Executive Director|
|Richard Sharp||- Non-Executive Director|
|Andrew Unitt||- Non-Executive Director|
Additional Senior Management within Oncimmune are:
|Dan Calvo||- Senior Advisor|
|Dr James Jett||- Chief Medical Officer|
|Andrea Murray||- Chief Operational Scientist|
|Greg Stanley||- President, Commercial Operations|
|Dr Neal Navani||- Consultant Clinical Director|
|Laura Peek||- Principal Scientist & Assistant Lab Director|
Please click here for information on the Scientific Advisory Board of Oncimmune.
Meinhard Schmidt (Non-Executive Chairman)
Meinhard is a MedTech industry executive and entrepreneur with more than 25 years broad international experience ranging from global General-, Operations-, Marketing- and Innovation Management. He is currently active as the founder and CEO at mt:onyx, an established Swiss-based service organization providing business partnering and business development in the area of Life Sciences, Diagnostics and Medical Devices industry. His activities include investments in start-ups with active board engagement and management support, consulting investors on identification of opportunities in the global MedTech industry and helping start-ups to establish business partnerships. Prior to this, he worked as an executive at Straumann AG (CH), responsible for the world-wide “Digitalization” of the Dental industry. Between 1998 and 2008, Meinhard was at Roche Diagnostics where he held various global senior leadership roles in Diabetes Care, Decentralized Solutions and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, programme and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at several healthcare/diagnostic companies in UK, Sweden and Switzerland.
Geoffrey Hamilton–Fairley (Chief Executive Officer)
Geoffrey has an entrepreneurial career that started in 1982 when Geoffrey founded a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon). In 1988, he joined the board of Abingdon as CEO and subsequently became sole owner having acquired the Company from its institutional shareholders. Abingdon had a number of quoted and unquoted investments – perhaps the most noteworthy being Fortronic, which developed the first magnetic strip plastic card swipe technology. In 1998 he launched Premium TV (PTV) securing a contractual joint venture with Eurosport to create “British Eurosport”. Later that year PTV was acquired by NTL (now Virgin Media). As CEO of PTV Geoffrey instigated and oversaw the highly complex development of the largest integrated broadband and internet sports broadcasting platform in the world at that time. Over the past ten years Geoffrey has increasingly focused his time and energies on the health sector and has dedicated almost all of his time in the past 8 years to the development of Oncimmune Limited, serving as its Executive Chairman and now CEO. Geoffrey is also a senior research fellow at the International Prevention Research Institute. His personal commitment to cancer detection can be traced to his father, the first medical oncologist in the United Kingdom.
Andrew Millet (Chief Finanical Officer)
Andrew is a Chartered Accountant and registered auditor. Andrew qualified as a chartered accountant with Stoy Hayward (now BDO), following which he gained an MBA from Henley Management College. Andrew has spent many years at executive level involved with the growth and success of early stage technology businesses. Andrew is a director of Wisteria Chartered Accountants, a firm he founded in 2002 and he has, since 2003, been involved in a variety of capacities with Oncimmune including as accountant, company secretary and shareholder.
Tim Bunting (Non-Executive Director (Deputy Chairman))
Tim joined Balderton Capital (UK) LLP as a partner in 2007 Balderton Capital (UK) LLP is the investment advisor to Balderton Capital Partners III, L.P. He was previously a partner of Goldman Sachs where he spent 18 years. At Goldman, Tim held various roles including Global Head of Equity Capital Markets (2002 to 2005) and Vice-Chairman of Goldman Sachs International (2005 to 2006). In 2006, he spent a period as non-executive chairman of Betfair. Tim is also a Governor of Wellington College and the Wellington Academy; a Trustee of the Rainbow Trust Children’s Charity and the Paul Hamlyn Foundation. Tim is a graduate of the University of Cambridge.
Julian Hirst (Non-Executive Director)
Julian is a seasoned finance executive with experience across a broad range of corporate finance transactions including equity private placements, initial public offerings, public debt and equity issues, mergers and acquisitions, trade sales, strategic partnerships and restructurings. Julian is currently Corporate Finance Director of Immunocore Limited, a leading UK biotechnology company specialising in immune-oncology. On a part-time basis, he also runs a single family office which represents a high profile hedge fund manager and is the Joint Head of Technikos, a partnership which manages stakes in spin-out companies from Oxford University's Institute on Bio-Medical Engineering. Prior to this, Julian held senior positions at several of the leading global investment banks including Panmure Gordon, UBS Warburg, Morgan Stanley and Lehman Brothers.
Richard Sharp (Non-Executive Director)
Richard graduated from Oxford University and began his professional career in 1978 working for JPMorgan in UK Banking, then in Investment Banking and Derivatives. In 1985, Richard joined Goldman Sachs in London and variously served as Head of Capital Markets, Head of UK investment Banking and Head of European Private Equity and Mezzanine Investing. Richard left Goldman in 2007 to found and run DII Capital LLP. Richard has been separately a trustee of the Royal Marsden Capital Fund and a trustee of the Institute of Cancer Research. In the summer of 2013, Richard became an External Appointee of HM Treasury on the Financial Policy Committee of the Bank of England which is responsible for Macro-Prudential Supervision in the UK.
Andrew Unitt (Non-Executive Director)
Andrew is the Chief Financial Officer for the University of Nottingham, which remains a major shareholder in Oncimmune. He joined the Board in 2014. Until 2013, when he joined the university, Andrew worked exclusively in commercial organisations and has been a Finance Director for 20 years. His more recent background includes 11 years at Boots plc, where he was Finance Director of Boots Healthcare International, its over the counter medicines business for 4 years, and Experian plc. He also works as a non-executive director within the NHS. Andrew graduated from the University of Cambridge in 1979.
Additional Senior Management within Oncimmune are:
Dan Calvo (Senior Advisor)
Dan served as President and CEO of Oncimmune USA since June 2009 until the acquisition of the US laboratory operations in October 2013. He is currently the President and CEO of Gyros, AB, a global immunoassay instrument Company. Prior to joining Oncimmune USA, Dan was the CEO of two successful companies, Cellomics and Assay Designs, each of which were acquired, by Fisher Scientific and Enzo Biochem respectively. He had a 20 year progressive career with DuPont, and then served as Commercial SVP of NEN Life Sciences, a spinout Company of DuPont, which was sold to PerkinElmer. Dan also served as global commercial VP there until joining Cellomics as CEO in 2003. He also serves as Chairman of the Board of Optra Systems, an India-based healthcare IT Company.
Dr James Jett (Chief Medical Officer)
Dr Jett’s research interests focus on the screening and early detection of lung cancer. His research has been funded by the National Institutes of Health and the National Cancer Institute and he was part of a research team that discovered how CT screening can be an effective tool to detect lung cancer early in high-risk patients. Dr Jett is board certified in internal medicine and pulmonary medicine, and he completed his medical degree at the University of Missouri, Columbia. He completed a residency in internal medicine and a fellowship in thoracic diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute, National Institutes of Health. He is on the Scientific Advisory Committee for the American Lung Association and was an External Review Chair for the Terry Fox Research Institute, Lung Cancer Grant. Dr Jett has served in journal review and editorial activities for many medical publications, including the American Journal of Respiratory and Critical Care Medicine, American Journal of the Medical Sciences, Cancer, Chest, International Journal of Cancer, Lung Cancer and The New England Journal of Medicine. Dr. Jett was editor-in-chief of the Journal of Thoracic Oncology from 2006 to 2012 and he is currently the Co-Editor of the Lung Cancer Section of the electronic textbook “Up-To-Date”.
Andrea Murray (Chief Operational Scientist)
Dr Murray studied Applied Biology at Nottingham Trent University before reading for a PhD in Pharmaceutical Sciences at the University of Nottingham. The focus of Dr Murray’s PhD studies, was the development of monoclonal antibodies for diagnosis of cancer. She later worked on the development of peptide mimetics for purification of monoclonal antibodies and antibody fragments and then spent three years developing radioimmunoconjugates for diagnosis and treatment of bladder cancer. During this postdoctoral research position, Dr Murray was awarded a travel fellowship by the European Association for Cancer Research which allowed her to spend a period of training at the Paul Scherrer Institute in Switzerland where she worked on the development of techniques for conjugating rhenium-188 to biological molecules such as antibodies. Dr Murray has published over 40 papers in peer reviewed journals and has written several book chapters and invited reviews. She has presented her work at numerous national and international conferences. When Dr Murray joined Oncimmune Limited in 2004 as Senior Director of Assay Development she was one of the Company’s first employees. Since then she has been involved with the EarlyCDT® platform through all of its stages of development and validation and has provided critical technical leadership.
Greg Stanley (President, Commercial Operations)
Mr. Stanley recently re-joined the company as President of Commercial Operations bringing extensive experience and expertise in the market development and commercial operations of diagnostic products and services He most recently served as Vice President of Sales and Marketing for Global Diagnostics Business Unit of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company. Prior to his position at OPKO Health, Mr. Stanley spent several years as Chief Commercial Officer at Oncimmune USA during the early stage and commercial ramp up phases of the company assisting in the successful transition to Health Diagnostic Laboratory in 2014. Prior to this, Mr. Stanley served over 5 years as Director of Marketing and then National Director of Corporate Accounts, for Roche Diagnostics where he led the successful market introduction of numerous diagnostic products. Mr. Stanley had increasing scope of responsibility in sales, marketing and executive management roles at Abbott Diagnostics, Chiron Corporation, and Radiometer prior to his time at Roche. He has been at the executive leadership level for almost 20 years and during his tenure served on the Board of Directors for Radiometer and Oncimmune USA.
Dr Neal Navani (Consultant Clinical Director)
Dr Navani qualified in Medicine from Cambridge and UCL in 2000 with distinction and several University prizes. He trained in Respiratory Medicine at the Brompton and Hammersmith Hospitals before winning a Medical Research Council Fellowship in 2008 and completing his PhD at UCL in 2011. He has also completed an MSc in Clinical Trials at the London School of Hygiene and Tropical Medicine. Dr Navani is a Consultant in Thoracic Medicine at University College London Hospital. He specialises in respiratory disorders and has particular expertise in patients with lung cancer and in bronchoscopy. He runs the regional Endobronchial Ultrasound (EBUS) service at UCLH and has performed over 3,000 procedures. Dr Navani is clinical lead for lung cancer services at UCLH and co-chairs the specialist lung cancer weekly MDT.
Dr Navani runs several clinical trials on the diagnosis and staging of lung disease and bronchoscopic techniques. He holds an honorary position at the Medical Research Council Clinical Trials Unit and is also a member of the UCLH early lung cancer detection and surveillance programme. Dr Navani has authored over 35 peer-reviewed publications, including leading articles on endobronchial ultrasound. He is the co-author of a textbook on respiratory disorders. He is an invited member of the British Thoracic Society guideline development group for bronchoscopy and is on the interventional procedures specialist advisory group. He is a member of the National Cancer Research Institute lung cancer clinical studies group. He sits on the lung cancer board of London Cancer and is a peer reviewer for many journals including PLOSoneand Thorax.
Laura Peek (Principal Scientist & Assistant Lab Director)
Dr. Laura J. Peek earned a Ph.D. with Honors in Pharmaceutical Chemistry from The University of Kansas(KU) in 2006 and was recognized with a Schering-Plough Science and Innovation Award for her doctoralresearch, which focused on characterizing the stability of biopharmaceutics, optimizing their formulationfor maximum stability and further evaluating their stability on surfaces of aluminum salt adjuvants,polymeric nanoparticles and microparticles. Throughout her doctoral studies, Dr. Peek received theMadison & Lila Self Graduate Fellowship, a competitive four-year multi-disciplinary doctoral fellowship atKU that provides extensive professional development training in preparation for future leadership roles.Dr. Peek went on to complete post-doctoral training at KU working on projects related to polymericparticle technology and drug delivery. In 2007, she joined Oncimmune USA LLC as the second employeeof the newly-formed US subsidiary and established the clinical laboratory operations from the ground up,including transfer of technology from the parent company in the UK, development of a comprehensivequality system and oversight of the laboratory’s regulatory compliance. Dr. Peek also played an integralrole in the validation, scale-up and commercial launch of EarlyCDT®-Lung and managed a prospectiveclinical audit of outcomes for 1600 patients, the results of which were published in the journal LungCancer. Dr. Peek is passionate about helping others and in her spare time enjoys mentoring studentsabout various career opportunities that exist in science. Dr. Peek currently serves on the Board ofTrustees for the Self Graduate Fellowship and is serving an elected 4-year term on the Board of Governorsfor the Society of Self Fellows.